First Affirmative Financial Network Boosts Stake in Sanofi (NASDAQ:SNY)

First Affirmative Financial Network boosted its stake in shares of Sanofi (NASDAQ:SNY) by 23.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,598 shares of the company’s stock after purchasing an additional 1,072 shares during the period. First Affirmative Financial Network’s holdings in Sanofi were worth $270,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of SNY. Synergy Asset Management LLC bought a new stake in Sanofi during the 4th quarter valued at approximately $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi during the third quarter valued at approximately $29,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares in the last quarter. Fortitude Family Office LLC increased its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 3.8 %

Shares of SNY opened at $54.15 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average of $49.12 and a 200 day moving average of $52.24. The company has a market cap of $137.42 billion, a PE ratio of 27.63, a P/E/G ratio of 1.21 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. On average, sell-side analysts expect that Sanofi will post 3.82 EPS for the current year.

Analyst Ratings Changes

SNY has been the topic of several research reports. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.